Evidence map›Paper›PMID 25406074›Full record

ArticlePloS one2014

A five-year experience of carbapenem resistance in Enterobacteriaceae causing neonatal septicaemia: predominance of NDM-1.

Saswati Datta, Subhasree Roy, Somdatta Chatterjee, Anindya Saha, Barsha Sen, Titir Pal, Tapas Som, Sulagna Basu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Molecular epidemiological analysis of blaAnnals of clinical microbiology and antimicrobials · 2024
    Article
  7. Carbapenem-resistantOpen forum infectious diseases · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Two Phenotypes ofInfection and drug resistance · 2022
    Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Clinical outcome of neonates with Carbapenem-resistantSouthern African journal of infectious diseases · 2021
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Saswati DattaDivision of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India.
Subhasree RoyDivision of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India.
Somdatta ChatterjeeDivision of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India.
Anindya SahaDepartment of Neonatology, Institute of Postgraduate Medical Education & Research, SSKM Hospital, Kolkata, West Bengal, India.
Barsha SenDepartment of Neonatology, Institute of Postgraduate Medical Education & Research, SSKM Hospital, Kolkata, West Bengal, India.
Titir PalAbsolutData Research and Analytics, Gurgaon, Haryana, India.
Tapas SomDepartment of Neonatology, Institute of Postgraduate Medical Education & Research, SSKM Hospital, Kolkata, West Bengal, India.
Sulagna BasuDivision of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India.
National Institute of Cholera and Enteric Diseases · INInstitute of Post Graduate Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of neonatal sepsis has become a challenge with the emergence of carbapenemase-producing bacteria. This study documents the trend of carbapenem susceptibility in Enterobacteriaceae that caused septicaemia in neonates over a five year period (2007-2011) and the molecular characterisation of Enterobacteriaceae resistant to carbapenems and cephalosporins. Hundred and five Enterobacteriaceae including Escherichia coli (n = 27), Klebsiella pneumoniae (n = 68) and Enterobacter spp. (n = 10) were isolated from blood of septicaemic neonates followed by antibiotic susceptibility tests, determination of MIC values, phenotypic and genotypic detection of β-lactamases. Carbapenem was the most active antimicrobial tested after tigecycline. CTX-M type was the most prevalent ESBL throughout the period (82%). New Delhi Metallo-β-lactamase-1 (NDM-1), which is a recent addition to the carbapenemase list, was the only carbapenemase identified in our setting. Fourteen percent of the isolates possessed blaNDM-1. Carbapenem non-susceptibility was first observed in 2007 and it was due to loss of Omp F/Ompk36 in combination with the presence of ESBLs/AmpCs. NDM-1 first emerged in E. coli during 2008; later in 2010, the resistance was detected in K. pneumoniae and E. cloacae isolates. NDM-1-producing isolates were resistant to other broad-spectrum antibiotics and possessed ESBLs, AmpCs, 16S-rRNA methylases, AAC(6')-Ib-cr, bleomycin resistant gene and class 1 integron. Pulsed field gel electrophoresis of the NDM-1-producing isolates indicated that the isolates were clonally diverse. The study also showed that there was a significantly higher incidence of sepsis caused by NDM-1-harbouring isolates in the male sex, in neonates with low birth weight and neonates born at an extramural centre. However, sepsis with NDM-1-harbouring isolates did not result in a higher mortality rate. The study is the first to review the carbapenem resistance patterns in neonatal sepsis over an extended period of time. The study highlights the persistence of ESBLs (CTX-Ms) and the emergence of NDM-1 in Enterobacteriaceae in the unit.

Indexed as

Drug Resistance, BacterialAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEnterobacteriaceaeFemaleHumansInfant, NewbornMalePorinsSepsisAnti-Bacterial Agentsbeta-lactamase NDM-1beta-LactamasesCarbapenemsOmpF proteinPorins

Identifiers

PMID25406074
PMCPMC4236051
OpenAlexW2129312703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.